Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy.
Because the number of patients requiring oral anticoagulation (OA) is steadily growing, more and more patients requiring surgical treatment of benign prostatic hyperplasia (BPH) are on OA. Laser treatment of BPH was said to offer a higher quality of hemostasis than transurethral resection of the prostate (TURP). Thus, laser was considered an interesting tool for BPH surgery in patients on OA therapy. To date, no randomized studies focusing on laser treatment in patients on OA are available. Compared to TURP, laser seems to decrease the risk of hemorrhage in patients on OA. Therefore, the laser could be considered a useful tool for managing patients on OA, and could be proposed as a first-line therapy for those patients requiring surgery. Continuing platelet aggregation inhibitors during the procedure is feasible. A switch to low molecular weight heparine medication prior to surgery is preferable to the continued use of OA during TURP. No conclusion can be reached regarding the preferred laser technique to treat these patients.
Berger
Julien
J
Department of Urology, CHU Limoges, 2 Avenue Martin Luther King, Limoges, 87042, France.
Robert
Gregoire
G
Descazeaud
Aurelien
A
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000601:surgery*
D000925:Anticoagulants
Urology. 1993 Dec;42(6):738-40
7504851
Br J Urol. 1998 Apr;81(4):520-2
9598620
N Engl J Med. 1997 May 22;336(21):1506-11
9154771
J Urol. 2006 Apr;175(4):1428-32
16516015
Eur Urol. 2008 Oct;54(4):893-901
18486311
Postgrad Med J. 2008 Jan;84(987):46-9
18230751
Eur Urol. 2007 Apr;51(4):1031-8; discussion 1038-41
16945475
J Intern Med. 2005 May;257(5):399-414
15836656
Tech Urol. 1998 Sep;4(3):156-9
9800899
J Urol. 1994 Jan;151(1):79-81
7504746
Aust N Z J Surg. 1995 Jan;65(1):40-3
7529490
BJU Int. 2008 Aug;102(3):322-7
18422772
J Endourol. 2005 Dec;19(10):1199-202
16359215
J Urol. 2003 Nov;170(5):1851-5
14532791
J Endourol. 2009 Aug;23(8):1343-6
19575692
Br J Urol. 1989 Dec;64(6):623-5
2627636
J Endourol. 2005 Dec;19(10):1196-8
16359214
J Endourol. 2008 Jul;22(7):1519-25
18613777
Cochrane Database Syst Rev. 2004;(1):CD001987
14973978
Eur Urol. 2008 Jan;53(1):160-6
17869409
J Urol. 2005 Jan;173(1):158-60
15592063
J Urol. 2002 Aug;168(2):610-3; discussion 614
12131319
Eur Urol. 2006 Nov;50(5):969-79; discussion 980
16469429
BJU Int. 1999 Jun;83(9):984-9
10368240
J Urol. 1999 Oct;162(4):1307-10
10492185
Int J Urol. 2008 Dec;15(12):1067-71
19054171